Effect of 35624® Alflorex® in Functional Gastrointestinal Disorders (FGIDs) in Children.

Inclusion Criteria:

1. Age 8-18 years
2. Any sex
3. ROME IV diagnostic criteria Pediatric functional digestive disorders: in children andadolescents. H2. Functional abdominal pain disorders H2a. Functional dyspepsia H2b.Irritable bowel syndrome H2d. Functional abdominal pain not otherwise specified H3.Functional defecation disorders H3a. Functional constipation H3b. Non-retentive fecalincontinence Meet the criteria during the last three months with the onset symptomsfor at least six months before diagnosis
4. IBS rated moderate to severe according to GSRS-IBS score (Spanish / LA)
5. At least two episodes of abdominal pain per week
6. No consumption of probiotics at least two weeks before baseline measurements (butpreferably four weeks);
7. Dad, Mom, or Guardian able to understand the protocol;
8. Be willing to maintain stable dietary habits throughout the study period;
9. Be able to communicate well with the Investigator, to understand and comply with therequirements of the study and be judged suitable for the study in the opinion of theInvestigator;
10. Signature of Informed Consent.

Exclusion Criteria:

1. Children with systemic, organic or metabolic diseases, immunosuppression, differentfrom IBS
2. Previous major abdominal surgery;
3. Consumption of proton pump inhibitors, H2 antagonists;
4. Consumption of probiotics in the two weeks before baseline measurements;
5. Are less than 8 or older than 18 years of age at the time of consent;
6. Subject who has been on antibiotics during the past 3 months;
7. Subjects who have not had at least two episodes of abdominal pain per week;
8. Subject with a malignant disease or any concomitant end-state organ disease and/orlaboratory abnormalities considered by Investigators to be risky or that couldinterfere with data collection;
9. Subject who are coeliac or lactose intolerant;
10. Known allergy to any of the components of the test product;
11. Participation in a clinical study with an investigational product within 60 daysbefore screening, or plans to participate in another study during the study period;
12. Subject has a history of non-compliance;
13. Use of dietary supplements or other fermented foods that contain live bacteria.
14. Pregnant or lactating females.